Steinberg Sarit
Chief Operating Officer at Israel Biotech Fund
Profile
Sarit Steinberg is a Partner at Israel Biotech Fund since 2015.
Prior to this, she worked as the General Counsel at Immune Pharmaceuticals Ltd.
from 2013 to 2015.
Ms. Steinberg holds a graduate degree from the London School of Economics & Political Science (2003) and a graduate degree from Queen Mary University of London (2002).
Steinberg Sarit active positions
| Companies | Position | Start |
|---|---|---|
Israel Biotech Fund
 Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Chief Operating Officer | 2020-01-31 |
Former positions of Steinberg Sarit
| Companies | Position | End |
|---|---|---|
Immune Pharmaceuticals Ltd.
 Immune Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Immune Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd. develops pharmaceutical products for the treatment of cancer and pain. The company is based in Herzliya-Pituach, Israel. Immune Pharmaceuticals was acquired by EpiCept Corp. on August 26, 2013 for $21.43 million. | General Counsel | 2015-04-30 |
Training of Steinberg Sarit
| London School of Economics & Political Science | Graduate Degree |
| Queen Mary University of London | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
Immune Pharmaceuticals Ltd.
Immune Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Immune Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd. develops pharmaceutical products for the treatment of cancer and pain. The company is based in Herzliya-Pituach, Israel. Immune Pharmaceuticals was acquired by EpiCept Corp. on August 26, 2013 for $21.43 million. | Health Technology |
- Stock Market
- Insiders
- Steinberg Sarit
